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The identification and use of “privileged structures” can increase the reliability and shorten the 
process in the drug discovery and drug design (a-b). Indane scaffolds occur in various natural 
products and they constitute the privileged structure that is ubiquitous in many biologically and 
pharmaceutically active molecules (c-e). Our research group has been working on the synthesis and 
pharmacological activity of nature identical and synthetically modified indanes and indanones for 20 
years. In the current study, the molecular design is centred on elaboration of a fern derived bioactive 
pharmacophore. The fern is used in traditional Taiwanese medicine to treat inflammation, allergy, 
stomach cramps and fever (f). Using a synthetic approach we have designed a novel chemical 
scaffold which can be modified to inhibit angiogenesis and 5-lipoxygenase activity. The parent 
scaffold and a number of strategically modified derivatives were initially screened using the Zebra 
fish (Danio rerio) model of tumour angiogenesis (g). This screen led to the identification of two lead 
molecules, which were then further evaluated in in vitro cell lines and colorectal explants. Results 
from these experiments establish that the lead compounds affect inter-segmental vessel formation. 
 These molecules also inhibit cell invasion and tube formation. When evaluated in ex vivo colorectal 
cancer explants where the molecules significantly affected angiogenic and inflammatory protein 
secretions. These small molecules also alter gene expression. Modification of the scaffold can inhibit 
5-lipoxygenase activity. These data suggest that the new scaffold may have significant potential in 
the treatment of angiogenesis and inflammatory related diseases. 
 
Bibliographic references: (a) Constantino & Barlocco, Curr Med Chem (2006) 13:65-85. (b) 
Bongarzone & Bolognesi, Expert Opin Drug Discov (2011) 6(3):251-268. (c) Chen et al., Molecules 
(2008) 13:255-266. (d) Syrchina & Semenov, Khim Prir Soedin (1982) 3-14. (e) Okpekon et al., Nat 
Prod Res (2009) 23:909-915. (f) Ho et al., Planta Med (1985) (2):148-50. (g) Tobia et al., Int J Dev Biol 
(2011) 55(4-5):505-9.  
 
 
 *Correspondence: chanki@tcd.ie 
 
 
